Effect of transarterial chemoembolization combined with camrelizumab on immune function and tumor markers in patients with primary liver cancer

Abstract

Abstract: Objective To explore the effectiveness of combining transarterial chemoembolization (TACE) with camrelizumab in treating primary liver cancer. Methods Ninety-six individuals with primary liver cancer treated in Shenmu City Hospital from January 2020 to January 2022 were randomly assigned into treatment group and control group. Two groups underwent TACE, and the observation group additionally received Camrelizumab for three months. The clinical efficacy was evaluated and the immune function, tumor marker levels, liver function, and serum levels of PD-1and VEGF were compared after three months of treatment. Progression-free survival (PFS) and survival rates over a 2-year follow-up period were also compared. Results The overall effective treatment rate for the treatment group was 78.17% (38/48), which was greater than the 54.17% (26 out of 48) in the control group. Following three months of therapy, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ ratios in the treatment group were (47.21±5.23)%, (34.71±4.04)%, and (2.11±0.42) respectively, and the levels of CD8⁺, tumor markers, liver function indicators, PD-1, and VEGF were reduced in the treatment group compared to the control group, all showing statistical significance (all P<0.05). PFS in 2-year and survival rates of the treatment group were (15.83±2.69) months and 79.17% (38/48) respectively, compared to (10.44±2.01) months and 54.17% (26/48) in the control group, with significant statistical differences observed (P<0.05). Conclusion TACE combined with Camrelizumab enhances immune function and reduces tumor marker levels in patients with primary liver cancer.

Key words: Transarterial chemoembolization, Camrelizumab, Primary liver cancer, Immune function, Tumor markers

LIU Mei-qiang, GAO Yong-jiang. Effect of transarterial chemoembolization combined with camrelizumab on immune function and tumor markers in patients with primary liver cancer[J]. Chinese Hepatolgy, 2025, 30(12): 1652-1655.

References

[1] Yang Y, Yu S, Lv C, et al. NETosis in tumour microenvironment of liver: from primary to metastatic hepatic carcinoma[J]. Ageing Res Rev, 2024, 97:102297.
[2] 陈水兵,贺辉,金诗湘,等. 原发性肝癌合并肝动静脉瘘患者经导管动脉化疗栓塞后早期联合射频消融治疗的临床研究[J].中国现代医学杂志,2023,33(4):51-55.
[3] Zhang B, Huang B, Yang F, et al. High-risk hepatocellular carcinoma: hepatic arterial infusion chemotherapy versus transarterial chemoembolization[J]. J Hepatocell Carcinoma, 2024, 11:651-663.
[4] 季德林,冯克海,谢韬. 卡瑞利珠单抗+白蛋白紫杉醇+奈达铂/顺铂治疗老年晚期食管癌的临床疗效观察[J]. 中国现代医学杂志,2022,32(23):6-10.
[5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志,2020,28(2):112-128.
[6] 邵梦扬. 实体瘤疗效综合评定标准[C]. 全国第三届中医肿瘤学术年会论文集.北京:中国中医药学会,2001:64-66.
[7] Yao Y, Huang X, Zhao C, et al. Summary of the evidence of best practices for the prevention and treatment of embolism syndrome after TACE in primary liver cancer[J]. Front Oncol, 2024, 13:1274235.
[8] 张学贤,丁雨寒,李威,等. 经导管动脉化疗栓塞联合仑伐替尼及卡瑞利珠单抗治疗中晚期肝细胞癌临床效果[J]. 介入放射学杂志,2024,33(1):57-62.
[9] Kong C, Zhao Z, Chen W, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE[J]. Eur Radiol, 2021, 31(10):7500-7511.
[10] Mikhail A S, Negussie A H, Mauda-Havakuk M, et al. Drug-eluting embolic microspheres: state-of-the-art and emerging clinical applications[J]. Expert Opin Drug Deliv, 2021, 18(3):383-398.
[11] 章腾,宋梦瑶,钱程,等. 肿瘤微环境中周细胞参与肿瘤转移的研究进展[J]. 中国药理学通报,2023,39(10):1819-1823.
[12] 曹广文. “癌症进化发育学”理论进展及其在肝细胞癌靶向/免疫治疗中的作用[J]. 肿瘤防治研究,2022,49(8):747-755.
[13] Liu K, Tan S, Jin W, et al. N-glycosylation of PD-1 promotes binding of camrelizumab[J]. EMBO Rep, 2020, 21(12):e51444.
[14] Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression[J]. Front Immunol, 2022, 13:874589.
[15] Bent E H, Millán-Barea L R, Zhuang I, et al. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy[J]. Nat Commun, 2021, 12(1):6218.
[16] Cheng M, Yang F, Yang Y, et al. Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer[J]. Cancer Chemother Pharmacol, 2024, 93(1):31-39.
[17] Zhang J X, Chen Y X, Zhou C G, et al. Efficacy and safety of the combination of transarterial chemoembolization with camrelizumab plus apatinib for advanced hepatocellular aarcinoma: a retrospective study of 38 patients from a single center[J]. Can J Gastroenterol Hepatol, 2022, 2022:7982118.
[18] Ghalehbandi S, Yuzugulen J, Pranjol M Z I, et al. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF[J]. Eur J Pharmacol, 2023, 949:175586.
[19] Xiang Y, Zhou X, Zhou H, et al. Limonin ameliorates cisplatin-induced acute liver injury by inhibiting 11β-hydroxysteroid dehydrogenase type 1[J]. Biomed Pharmacother, 2023, 168:115680.
[20] Ren Y, Guo Y, Chen L, et al. Efficacy of drug-eluting beads transarterial chemoembolization plus camrelizumab compared with conventional transarterial chemoembolization plus camrelizumab for unresectable hepatocellular carcinoma[J]. Cancer Control, 2022, 29:10732748221076806.